비후성 및 켈로이드 흉터 치료 시장 : 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global hypertrophic and keloid scar treatment market size is expected to reach USD 1898.48 Million in 2034 from USD 772.31 Million in 2025, growing at a CAGR of 10.51 during 2026-2034.The Global Hypertrophic and Keloid Scar Treatment Market has expanded due to increasing awareness of cosmetic and dermatological treatments. Rising incidence of surgical procedures, burns, and traumatic injuries has contributed to greater demand for scar management solutions. Advances in minimally invasive procedures and laser therapies have improved treatment outcomes. Growing consumer focus on aesthetic appearance further supports market growth.

Key growth drivers include technological advancements in corticosteroid injections, cryotherapy, silicone gel sheets, and laser-based treatments. The increasing availability of dermatology clinics and aesthetic centers worldwide has enhanced access to specialized care. Social media influence and rising disposable incomes also encourage consumers to seek cosmetic treatments. Additionally, ongoing research into regenerative medicine is expanding therapeutic options.

Looking ahead, the market is expected to grow steadily with continuous innovation in non-invasive and combination therapies. Emerging markets offer strong growth potential due to expanding healthcare infrastructure. Increasing investment in dermatology research will enhance product development. As patient demand for effective and affordable scar treatments rises, the market will continue to evolve.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Scar Type

• Hypertrophic
• Keloid

By Product Type

• Topical Laser Products
• Products
• Injectables
• Other

By End User

• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• Alliance Pharma PLC, Molnlycke Health Care AB, Smith & Nephew plc, Newmedical Technology Inc., Rejuvaskin, Sonoma Pharmaceuticals, Inc., Suneva Medical, HRA Pharma, Lumenis Ltd., Perrigo Company plc, Beiersdorf AG, Hugel, Inc., Sanofi S.A., Pfizer Inc., L'Oreal S.A., Medtronic plc, Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Galderma SA

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BY SCAR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Scar Type
• 4.2. Hypertrophic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Keloid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Topical Laser Products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Scar Type
  • 7.2.2 By Product Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Scar Type
  • 7.3.2 By Product Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Scar Type
  • 7.4.2 By Product Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Scar Type
  • 7.5.2 By Product Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Scar Type
  • 7.6.2 By Product Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Alliance Pharma PLC
  • 9.2.2 Molnlycke Health Care AB
  • 9.2.3 Smith & Nephew Plc
  • 9.2.4 Newmedical Technology Inc
  • 9.2.5 Rejuvaskin
  • 9.2.6 Sonoma PharmaceuticalsInc
  • 9.2.7 Suneva Medical
  • 9.2.8 HRA Pharma
  • 9.2.9 Lumenis Ltd
  • 9.2.10 Perrigo Company Plc
  • 9.2.11 Beiersdorf AG
  • 9.2.12 HugelInc
  • 9.2.13 Sanofi S.A
  • 9.2.14 Pfizer Inc
  • 9.2.15 L'Oreal S.A
  • 9.2.16 Medtronic Plc
  • 9.2.17 Novartis AG
  • 9.2.18 Johnson & Johnson
  • 9.2.19 GlaxoSmithKline Plc
  • 9.2.20 Galderma SA